Generation of murine tumor models refractory to αPD-1/-L1 therapies due to defects in antigen processing/presentation or IFNγ signaling using CRISPR/Cas9.
Immune checkpoint blockade (ICB) targeting the programmed cell death protein 1 (PD-1) and its ligand 1 (PD-L1) fails to provide clinical benefit for most cancer patients due to primary or acquired resistance. Drivers of ICB resistance include tumor antigen processing/presentation machinery (APM) and...
Main Authors: | Paul L Chariou, Christine M Minnar, Mayank Tandon, Mary R Guest, Raj Chari, Jeffrey Schlom, Sofia R Gameiro |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2024-01-01
|
Series: | PLoS ONE |
Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0287733&type=printable |
Similar Items
-
Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies
by: Jeffrey Schlom, et al.
Published: (2022-06-01) -
Integrated CRISPR-Cas9 System-Mediated Knockout of IFN-γ and IFN-γ Receptor 1 in the Vero Cell Line Promotes Viral Susceptibility
by: Suyeon Kim, et al.
Published: (2022-07-01) -
Role of interferon-gamma (IFN-γ) and IFN-γ receptor 1/2 (IFNγR1/2) in regulation of immunity, infection, and cancer development: IFN-γ-dependent or independent pathway
by: Huihui Ding, et al.
Published: (2022-11-01) -
Abrogation of IFN-γ Signaling May not Worsen Sensitivity to PD-1/PD-L1 Blockade
by: Julie Vackova, et al.
Published: (2020-03-01) -
IFN-γ Induces PD-L1 Expression in Primed Human Basophils
by: Srinivasa Reddy Bonam, et al.
Published: (2022-02-01)